| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/10/2001 | US6258789 Delivery of gene products by intestinal cell expression |
| 07/10/2001 | US6258775 Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses |
| 07/10/2001 | US6258562 Human antibodies that bind human TNFα |
| 07/10/2001 | CA2214629C Receptor activation by gas6 |
| 07/10/2001 | CA2175643C Utilization of retinoids in a cosmetic composition or in the preparation of a pharmaceutical composition |
| 07/10/2001 | CA2059792C Tricyclic compounds and intermediates thereof |
| 07/05/2001 | WO2001048483A2 Method for screening of appetite control agents |
| 07/05/2001 | WO2001048163A2 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 07/05/2001 | WO2001048162A2 Method for the production of vitamin a |
| 07/05/2001 | WO2001047946A2 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 07/05/2001 | WO2001047943A1 Antisense modulation of akt-3 expression |
| 07/05/2001 | WO2001047935A2 Novel bisamidate phosphonate prodrugs |
| 07/05/2001 | WO2001047931A1 Fused purine derivatives |
| 07/05/2001 | WO2001047922A2 Azaindoles |
| 07/05/2001 | WO2001047921A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | WO2001047905A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047899A1 Substituted piperazine derivatives as mtp inhibitors |
| 07/05/2001 | WO2001047898A2 Substituted piperazine derivatives and their use as inhibitors of the microsomal triglyceride transfer protein (mtp) |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047891A1 Heterocyclic compounds having sulfonamide groups |
| 07/05/2001 | WO2001047887A1 β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047878A1 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 07/05/2001 | WO2001047866A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047557A1 Oral preparations for diabetes |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047529A2 Association of deoxyfructosazine and an antidiabetic agonist of the peroxysome proliferator gamma-activated receptor |
| 07/05/2001 | WO2001047528A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | WO2001047527A1 Association of deoxyfructosazine and an antidiabetic of the sulphonylurea family |
| 07/05/2001 | WO2001047522A2 Association of deoxyfructosazine and an antidiabetic of the biguanide family |
| 07/05/2001 | WO2001047520A1 Thiazolidinedione derivatives in treatment of diabetes mellitus of type 2 |
| 07/05/2001 | WO2001047519A1 Powdery biotin preparations |
| 07/05/2001 | WO2001047514A1 Use of hypoglycemic agent for treating impaired glucose metabolism |
| 07/05/2001 | WO2001047510A2 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 07/05/2001 | WO2001047509A2 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
| 07/05/2001 | WO2001047506A2 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 07/05/2001 | WO2001047498A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2001000654A3 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000055137A8 Compounds and methods for modulation of estrogen receptors |
| 07/05/2001 | WO2000040247A8 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010006971 Administering an antiallergen of loratadine or metabolite of loratadine, desloratadine; migraines, stroke, orthostatic hypotension, gastrointestinal stasis, nausea, dizziness and jet lag; also psychological disorders; 5-HT7 receptors |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006942 Inducing an immune response against a chemokine receptor molecule by administering an immunogenic chemokine receptor polypeptide from an extracellular region of a chemokine receptor molecule; treating inflammation, multiple sclerosis |
| 07/05/2001 | US20010006941 Composition for inhibiting increase of blood sugar level or lowering blood sugar level |
| 07/05/2001 | US20010006662 A lipid regulating agent selected from a fibrate or statin dispersed or dissolved in a hydrophilic, amorphous polymer in which antilipidimic agent present as metastable, amorphous phase |
| 07/05/2001 | US20010006640 Compounds and methods to inhibit or augment an inflammatory response |
| 07/05/2001 | DE19963235A1 Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel Substituted piperazine derivatives, their preparation and their use as medicaments |
| 07/05/2001 | DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases |
| 07/05/2001 | CA2699568A1 Azaindoles |
| 07/05/2001 | CA2396713A1 Novel bisamidate phosphonate prodrugs |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396516A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 07/05/2001 | CA2396502A1 Substituted pyrrole mannich bases |
| 07/05/2001 | CA2396039A1 Gfr.alpha.1-ret specific agonists and methods therefor |
| 07/05/2001 | CA2395993A1 Antidiabetic preparation for oral administration |
| 07/05/2001 | CA2395535A1 Method for the production of vitamin a |
| 07/05/2001 | CA2395414A1 Condensed purine derivative |
| 07/05/2001 | CA2395305A1 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395249A1 Substituted piperazine derivatives, the preparation thereof and their use as medicaments |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2395003A1 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2394644A1 Substituted piperazine derivatives,the preparation thereof and their useas medicaments |
| 07/05/2001 | CA2394098A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2392866A1 Substituted indole mannich bases |
| 07/04/2001 | EP1113015A1 Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
| 07/04/2001 | EP1113014A1 Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them |
| 07/04/2001 | EP1113007A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 07/04/2001 | EP1112364A2 Stomach polypeptide zsig28 |
| 07/04/2001 | EP1112362A2 GENE MODIFICATION IN THE GENE FOR THE DIE G$g(b)3-SUB-UNIT OF HUMAN G-PROTEIN |
| 07/04/2001 | EP1112275A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 07/04/2001 | EP1112266A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 07/04/2001 | EP1112251A1 Azetidine derivatives, preparation and medicines containing them |
| 07/04/2001 | EP1112088A1 Method for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| 07/04/2001 | EP1112073A1 Calcilytic compounds |
| 07/04/2001 | EP1112072A2 Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases |
| 07/04/2001 | EP1112064A1 Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications |
| 07/04/2001 | EP1112063A1 Lipstatin derivative-soluble fiber tablets |
| 07/04/2001 | EP1112005A1 Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid |
| 07/04/2001 | EP0896538B1 Use of activity inhibiting dipeptidyl peptidase iv effectors for lowering the blood glucose level in mammals |
| 07/04/2001 | EP0736038B1 Compounds with growth hormone releasing properties |
| 07/04/2001 | EP0666746B1 $g(D)5-ANDROSTENES USEFUL FOR PROMOTING WEIGHT MAINTENANCE OR WEIGHT LOSS AND TREATMENT PROCESS |
| 07/04/2001 | CN1302296A Novel 2-alkyl substituted imidazole compounds |
| 07/04/2001 | CN1302206A Therapeutic uses of quinoline derivatives |
| 07/04/2001 | CN1302204A Novel fatty analogues for treatment of diabetes |
| 07/04/2001 | CN1301699A New direct chain or cyclic urea, its preparing method and medicinal composition containing them |
| 07/04/2001 | CN1301692A Higher fatty alcohol aliphatic ester and use thereof |
| 07/04/2001 | CN1301691A New L-threonic acid derivatives |
| 07/04/2001 | CN1301556A 三七软胶囊 Thirty-seven soft capsules |